leadf
logo-loader
viewHelix BioPharma Corp.

Helix BioPharma set to build on early successes as it extends immunotherapy collaboration with Moffitt cancer center

Helix and Moffitt have already developed a new pancreatic adenocarcinoma mouse model suitable for testing Helix's lead clinical compound L-DOS47

Helix BioPharma Corp. -
The company's lead candidate L-DOS47 is in Phase II clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer

Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF), the immuno-oncology focused biotech, told investors it has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far.

Helix and Moffitt have already developed a new pancreatic adenocarcinoma mouse model suitable for testing Helix's lead clinical compound L-DOS47 alone or in combination with immunotherapies, the group noted.

READ: Helix BioPharma to divest its remaining shares in Polish subsidiary Helix Immuno-Oncology

In addition, last year, at the World Molecular Imaging Conference, the firms jointly presented a poster presentation on the pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer (CEST) and 31P-magnetic resonance spectroscopy (31P-MRS). This imaging technique is currently being used in Helix BioPharma's US clinical study in advanced stage pancreatic patients.

The company's lead candidate L-DOS47 is in Phase II clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer.

In this next stage of the partnership, Helix and Moffit intend to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.

"I look forward to expanding the use of L-DOS47 in combination with immunotherapy for future clinical application", Dr Heman Chao, Helix's chief executive said in a statement.

L-DOS47 is based on the firm's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a way that leads to their destruction.

Contact the author at giles@proactiveinvestors.com

Quick facts: Helix BioPharma Corp.

Price: 0.435 CAD

TSX:HBP
Market: TSX
Market Cap: $57.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Helix BioPharma extends Moffitt cancer center collaboration to further...

Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF) CEO Heman Chao tells Proactive the immuno-oncology focused biotech has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far. Chao says Helix and Moffitt have already...

on 13/8/20

2 min read